Use of botulinum toxin type A in rheumatic diseases
Open Access
- 20 October 2021
- journal article
- research article
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 15 (5) , 108-113
Abstract
The article presents an analysis of modern data on the antinociceptive effectiveness of botulinum toxin type A (BTA) in rheumatic diseases (RD). The prospects for the use of BTA in the treatment of pain in different RDs are discussed. We searched for publications in the Medline, Pubmed, Cochrane Library databases. Analysis of literature data has shown that BTA can become an additional method of pain management in many RDs.Keywords
This publication has 47 references indexed in Scilit:
- The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma‐Associated Raynaud's Phenomenon: A Randomized, Double‐Blind, Placebo‐Controlled Clinical TrialArthritis & Rheumatology, 2017
- Usefulness of intra-articular botulinum toxin injections. A systematic reviewJoint Bone Spine, 2016
- Intérêt de la toxine botulinique de type A dans le traitement des syndromes de Raynaud sévères secondaires à la sclérodermie systémiqueAnnales de Chirurgie Plastique Esthétique, 2013
- Botulinum Toxin-A for the Treatment of Raynaud SyndromeArchives of Dermatology, 2012
- Botulinum Toxin Type A in the Treatment of Raynaud's PhenomenonThe Journal of Hand Surgery, 2010
- Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1FEBS Letters, 2010
- Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: A report of two casesJoint Bone Spine, 2009
- Long term effects of intra-articular botulinum toxin a for refractory joint painNeurotoxicity Research, 2006
- Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatmentEuropean journal of pain, 2006
- The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and catsAnnals of Neurology, 1993